©2016 Bloomberg News O0GH0E6S9729 (Bloomberg) — Editas Medicine Inc., the drugmaker whose backers include Bill Gates and Google Ventures, filed to become the first publicly traded company to specialize in a new technology to edit flaws in genes. The company, which uses a gene-editing technique called Crispr, filed Monday for

published Dec 5th 2016, 11:01 pm, by Jeanna Smialek (Bloomberg) — It’s the most wonderful time of the year, and if you’re a typical American, it’ll cost you about $728. That’s how much the average U.S. adult who planned to buy holiday presents expected to spend in 2015. How they